P3-16-07: Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: Results from the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study.

A. Stopeck, Ada Braun, Denise A. Yardley et al.|Cancer Research|2011

Cited by 15